deutsch english

Multi-well plate for automated and reliable tissue-based drug screening

The engineering of 3-dimensional (3D) tissue has undergone exciting progress for the past decade due to advances in human stem cell biology, tissue engineering and material sciences. Yet, preclinical compound or tox screenings still rely on 2D cell culture with poor predictive power. As tissue engineering from stem cells has matured and become more and more accepted, it has the capabilities to replace 2D-cell culture. Scientists at University of Göttingen, Medical Department developed a new device (multi-well tissue plate) for automated and reliable tissue engineering & drug testing.

Challenge

Limitations of today's 2D cell cultures have contributed to poor predictive power of preclinical cell-based drug and toxicity screening assays. in fact, more than 90% of drugs that pass through in vitro preclinical studies fail to meet the desired efficacy or safety required in subsequent clinical trials.
Due to recent advances in stem cell technologies, in vitro 3D cell culture (tissue engineering) have become increasingly sophisticated and are now widely used in the research community. However, to become a powerful and reliable tool in preclinical tissue-based drug and toxicity screening, new procedures and devices for a consistent and automated tissue engineering of multiple micro tissues as well as an automated screening have to be developed.

Our Solution

Scientists at University of Göttingen, Medical Department developed multi-well tissue plates for automated and reliable tissue engineering & drug testing. This will allow for a reliable and consistent production of multiple human micro tissues (e.g. heart muscle tissue rings) and a subsequent automated drug screening and monitoring within the very same multi-well plate under SOP and GMP.

Advantages

  • New 3in1 tissue culture multi-well plate combining three steps:
    • Culturing & condensing of cells
    • Maturating into a micro-tissue
    • Automated drug or toxicological screening.
  • Standardized growth of any type of self-condensing cell mixtures into a  homogeneous ring-shaped tissue (Organ-on-a-Chip).
  • Screening & production of human micro tissue rings under GMP and SOP in combination with newly developed serum-free production.
  • Optimized for automated video analysis - simple, robust and reliable.

Applications

Preclinical drug or toxicological screening.

Developmental Status

The device has been successfully tested for automated preclinical cardiotoxic screenings on human heart muscle rings in a 48-well plate format.

Patent Status

A priority patent application has been filed (Applicant: Georg-August-University Göttingen public law foundation).

References

WO2015025030
WO2015040142
AG Zimmermann

Contact

Dr. Stefan Uhle
Patent Manager Life Science
E-Mail: suhle(at)sciencebridge.de
Tel: +49 551 30724 154
Reference: BioC-1853-UMG

Download als PDF
Die Fusszeile

Eine Tochter der